If you have been reading about Peptide profile and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
The parent whey proteins include beta-lactoglobulin, alpha-lactalbumin, serum albumin, immunoglobulins, and glycomacropeptide, depending on the whey source. Hydrolysis does not remove these sequences; it fragments them into peptides of varying length. The peptide distribution depends on the enzyme specificity, reaction time, temperature, pH, and enzyme-to-substrate ratio. Because the mixture is heterogeneous, a single molecular weight cannot describe the product. Instead, laboratories report a distribution, often spanning from a few hundred to several thousand daltons.
Whey protein hydrolysate appears in foods and supplements where rapid digestion, low viscosity, or reduced intact-protein content is desired. It is distinct from whey protein isolate and concentrate, which contain largely intact proteins, though hydrolysates can be made from either. In infant formula, extensively hydrolyzed whey is used in some specialty products, while partially hydrolyzed forms appear in other formulations. Human health effects depend on the specific peptide mixture and are not uniform across all hydrolysates.
Whey protein hydrolysate is a dairy ingredient made by breaking peptide bonds in whey proteins. Enzymes such as proteases, or in some processes acid or heat, cleave the protein chains into shorter peptides and free amino acids. The starting material may be sweet whey, acid whey, whey protein concentrate, or whey protein isolate. Because raw materials and reaction conditions differ, the final mixture is not a single uniform substance. Its peptide profile, mineral content, and residual lactose depend on the source and the processing steps used.
Production typically begins with pasteurization and concentration of whey. A protease is added under controlled temperature and pH, and the reaction is stopped by heat or pH change when the target extent of cleavage is reached. Ultrafiltration or diafiltration may remove enzymes, salts, and small molecules. The liquid is then spray dried into a powder. Process parameters shape bitterness, solubility, and peptide size. Established control points include enzyme type, reaction time, and inactivation conditions. How these variables interact across large-scale batches remains an area of active process development.
Hydrolysates usually contain 70% to 90% protein on a dry basis, with variable ash, fat, and carbohydrate. Solubility in water is generally high over a broad pH range, though bitter notes can appear from exposed hydrophobic peptides. The powder tends to absorb moisture and may brown during prolonged warm storage. Applications span sports nutrition, clinical nutrition, infant formulas, and flavor systems. Regulatory status and labeling rules differ by country. A key open question is whether a given peptide profile reliably predicts functional or sensory behavior across different food matrices.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Whey hydrolysate; hydrolyzed whey protein | Abbreviations such as WPH appear in ingredient lists |
| Appearance | Off-white to light cream powder | Color can vary with starting whey and drying method |
| Solubility class | Highly soluble in water | Short peptides often dissolve more readily than intact whey protein |
| Typical storage temperature | 15–25 °C | Cool, dry conditions limit moisture uptake and browning reactions |
| Typical analytical method | Size-exclusion chromatography | Used to estimate molecular weight distribution of peptides |
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteolytic enzymes. The starting material is whey, the liquid remaining after cheese or casein production, and its main proteins include beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. Enzyme action breaks peptide bonds, producing shorter peptides and some free amino acids. The result is not a single uniform substance; composition depends on whey source, enzyme type, hydrolysis conditions, and downstream filtration. Hydrolysates are often described by average peptide length or degree of hydrolysis rather than by one fixed molecular weight.
Compared with whey protein concentrate or isolate, hydrolysate has a smaller average peptide size and a higher proportion of low-molecular-weight fractions. This change can affect solubility, viscosity, osmolality, taste, and foam formation. Some hydrolysates are bitter because hydrophobic peptides are exposed during cleavage. The term hydrolysate does not indicate a guaranteed peptide profile; two products with the same reported hydrolysis value can differ in peptide sequence and residual intact protein. Commercial specifications usually state protein content, moisture, ash, fat, and microbiology, while peptide distribution may be reported as a range.
Whey protein hydrolysate appears in infant formula, sports nutrition, and clinical nutrition. In infant formula, extensively hydrolyzed products are used when a reduced allergenicity is desired, though not all hydrolysates are hypoallergenic. In sports products, the ingredient is marketed for rapid amino acid delivery, but the practical advantage over intact whey protein remains debated. Research often compares hydrolysate with isolate or concentrate for absorption kinetics, muscle protein synthesis, and gastrointestinal tolerance. Regulatory categories differ by country, and label terms such as partially hydrolyzed or extensively hydrolyzed are defined in some jurisdictions but not others.
Whey protein hydrolysate is a dairy-derived ingredient made by treating whey protein with enzymes or acid to break peptide bonds. The starting material is typically sweet whey or acid whey from cheese manufacture, which contains beta-lactoglobulin, alpha-lactalbumin, bovine serum albumin, and immunoglobulins. Hydrolysis shortens protein chains into peptides and free amino acids, changing solubility, viscosity, and taste. The extent of breakdown is described by degree of hydrolysis, a percentage of cleaved peptide bonds. This value influences functional and sensory properties but does not by itself define a specific molecular profile.
Commercial production usually begins with whey protein concentrate or isolate, not raw whey, to reduce fat and lactose. Food-grade proteases from bacterial or plant sources are added under controlled temperature and pH, then inactivated by heat or pH adjustment. The resulting liquid may be clarified, filtered, concentrated, and spray-dried into powder. Enzyme choice, reaction time, and pretreatment conditions create products with different peptide size distributions. Because these variables are proprietary and not standardized, two hydrolysates with the same degree of hydrolysis can differ in peptide sequences and mineral content.
Level instrumentation determines the height of liquids by measuring the position of a gas/liquid or liquid/liquid interface within the vessel or tank. Such interfaces include oil/gas, oil/water, condensate/water, glycol/condensate, etc. Local indication (LI) includes sight glasses which show the liquid level directly through a vertical glass tube attached to the vessel/tank. Phase interfaces are maintained at a constant level by level transmitters (LT) transmitting a signal to a level controller (LIC) which compares the measured value with the desired set point. The difference is sent as a signal to a level control valve (LCV) on the liquid outlet from the vessel. As the level rises the controller acts to open the valve to draw off liquid to reduce the level. Similarly as the levels fall the controller acts to close the LCV to reduce outflow of fluid. Some vessels store liquid until it is pumped out. The controller (LIC) acts to start and stop the pump within a specified band. For example, it may start the pump when the level rises to 0.6 m and stop the pump when the level falls to 0.4 m. High and low level alarms (LAH and LAL) warn operating personnel that levels are outside predefined limits. Further deviation (LAHH and LALL) initiates a shutdown either to close emergency shutdown valves (ESDV) on the inlet to the vessel or on the liquid outlet lines. As with high and low pressure instrumentation the shutdown function comprises an independent measurement loop to prevent a common mode failure.
=== Blood nerve barrier === The peripheral blood nerve barrier is analogous to the blood brain barrier. Like the blood brain barrier, the blood nerve barrier creates a stable, privileged environment where certain substances cannot pass through due to tight junctions. The blood nerve barrier is made up of inner cells of the perineurium and the endothelial cells of the endoneurial microvessels.
=== Equipment === Commonly used equipment for resistance training include free weights—including dumbbells, barbells, and kettlebells—weight machines, and resistance bands. Resistance can also be generated by inertia in flywheel training instead of by gravity from weights, facilitating variable resistance throughout the range of motion and eccentric overload. Some bodyweight exercises do not require any equipment, and others may be performed with equipment such as suspension trainers or pull-up bars.
Sources: en.wikipedia.org
Compiègne, Oise, Hauts-de-France, France Xiangyang, Hubei province, China Kingston upon Hull, England Rostock, Mecklenburg-Vorpommern, Germany Nairobi, Kenya Gibraltar, Gibraltar (overseas territory of the United Kingdom)
==== MeSH D06.472.317 – gastrointestinal hormones ==== MeSH D06.472.317.152 – cholecystokinin MeSH D06.472.317.152.700 – sincalide MeSH D06.472.317.350 – epidermal growth factor MeSH D06.472.317.400 – gastric inhibitory polypeptide MeSH D06.472.317.410 – gastrin-releasing peptide MeSH D06.472.317.413 – gastrins MeSH D06.472.317.413.593 – pentagastrin MeSH D06.472.317.413.800 – tetragastrin MeSH D06.472.317.469 – glucagon precursors MeSH D06.472.317.469.500 – enteroglucagons MeSH D06.472.317.469.500.500 – glucagon-like peptide 1 MeSH D06.472.317.525 – motilin MeSH D06.472.317.662 – peptide yy MeSH D06.472.317.800 – secretin MeSH D06.472.317.950 – vasoactive intestinal peptide
the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers, including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success. According to a 2014 report, the orphan drug market has become increasingly lucrative for a number of reasons. The cost of clinical trials for orphan drugs is substantially lower than for other diseases because trial sizes are naturally much smaller than for more diseases with larger numbers of patients. Small clinical trials and minimal competition place orphan agents at an advantage in regulatory review. Tax incentives reduce the cost of development. On average the cost per patient for orphan drugs is "six times that of non-orphan drugs, a clear indication of their pricing power". The cost of per-person outlays are large and are expected to increase with wider use of public subsidies. The 2014 Orphan Drug report stated that the percentage of orphan drug sales as part of all prescription drug sales had been increasing at a rapid rate. The report projected a total of US$176 billion by 2020.
Sources: en.wikipedia.org
Alniditan (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name R-91274) is a selective serotonin 5-HT1B and 5-HT1D receptor agonist with migraine-preventive effects which was never marketed. It was under development for treatment of migraine via subcutaneous injection in the 1990s and reached phase 3 clinical trials for this indication prior to the discontinuation of its development.
Many surgical procedures have been developed to create a neovagina, but none of them are ideal. Surgical intervention should only be considered after non-surgical pressure dilation methods have failed to produce a satisfactory result. A study in 2025 claims that vaginoplasty is not recommended in CAIS individuals. Neovaginoplasty can be performed using skin grafts, a segment of bowel, ileum, peritoneum, an absorbable adhesion barrier (Intercede, made by Johnson & Johnson), buccal mucosa, amnion, dura mater. or with the support of vaginal stents/expanders. Success of such methods should be determined by sexual function, and not just by vaginal length, as has been done in the past. Ileal or cecal segments may be problematic because of a shorter mesentery, which may produce tension on the neovagina, leading to stenosis. The sigmoid neovagina is thought to be self-lubricating, without the excess mucus production associated with segments of small bowel. Vaginoplasty may create scarring at the introitus (the vaginal opening), which requires additional surgery to correct. Vaginal dilators are required postoperatively to prevent vaginal stenosis from scarring. Inflatable vaginal stents are placed in the vagina deflated and then gently inflated. Other complications include bladder and bowel injuries. Yearly exams are required as neovaginoplasty carries a risk of carcinoma, although carcinoma of the neovagina is uncommon. Neither neovaginoplasty nor vaginal dilation should be performed before puberty.
Hydrophilic interaction chromatography (or hydrophilic interaction liquid chromatography, HILIC) is a type of liquid chromatography that uses a hydrophilic stationary phase and a high-organic mobile phase for the separation of analytes by polarity. While it is not as popular as some other types of liquid chromatography, the number of scientific publications using HILIC have greatly increased since the early 2000s. HILIC is similar to reverse phase chromatography in its mobile phase composition, and also to normal phase chromatography, with its polar stationary phase. It also has overlap with ion exchange chromatography. Sometimes, HILIC is considered to be a hybrid of these techniques. HILIC was named in 1990 by Andrew Alpert, who described it as a type of liquid-liquid partition chromatography. He suggested that analytes elute in order of increasing polarity, a conclusion supported by review and re-evaluation of published data. The mechanism for HILIC is still not entirely understood, but it is thought to rely on analytes partitioning between the organic-rich mobile phase and a water-enriched layer that forms of the surface of the polar stationary phase, in a liquid-liquid extraction system. More polar analytes will have stronger interactions with the water-enriched layer and with the column itself, therefore being retained on the column for longer.
Sources: en.wikipedia.org
It is made from whey, a byproduct of cheese or casein production, or from whey protein concentrate or isolate. Enzymes break the intact whey proteins into shorter peptides. The final composition depends on the starting whey and the hydrolysis conditions.
No. Whey protein isolate is a purified intact protein, while hydrolysate has been enzymatically cleaved into smaller peptides, and hydrolysate can be produced from isolate or concentrate. The two ingredients differ in molecular size, taste, and functional behavior.
Hydrolysis cleaves proteins but does not necessarily remove lactose, which is a sugar. It can reduce the size of allergenic proteins, yet residual peptides may still trigger reactions in sensitive individuals. Allergen status depends on the extent of hydrolysis and must be assessed for each product.
Hydrolysis extent indicates the share of peptide bonds that have been cleaved. It is often estimated from free amino groups and is reported as a percentage. A higher value means smaller peptides and more free amino acids, but it does not by itself define product quality.